Permax

Parkinson's Disease
Treatment
2 FDA approvals
20 Active Studies for Permax

What is Permax

PergolideThe Generic name of this drug
Treatment SummaryPergolide is a medication used to treat symptoms of Parkinson’s Disease. It works by stimulating the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was initially approved in 1982 and used as an add-on medication with levodopa/carbidopa, but was later found to increase the risk of cardiac valvulopathy and was removed from the US and Canadian markets in 2007. Today, it is mainly used for veterinary purposes.
Pergolide Mesylateis the brand name
image of different drug pills on a surface
Permax Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Pergolide Mesylate
Pergolide
2002
9

Approved as Treatment by the FDA

Pergolide, also known as Pergolide Mesylate, is approved by the FDA for 2 uses such as Parkinson's Disease (PD) and Parkinson's Disease .
Parkinson's Disease (PD)
Used to treat Parkinson's Disease (PD) in combination with Carbidopa
Parkinson's Disease
Used to treat Parkinson's Disease (PD) in combination with Carbidopa

Effectiveness

How Permax Affects PatientsPergolide works by stimulating certain parts of the brain to improve symptoms of movement disorders. It affects five types of dopamine receptors, namely D1, D2, D3, D4, and D5. The D2 and D3 receptors are particularly important for treating Parkinson's, as they help reduce symptoms like slow movements, tremors, and stiffness. It can also help protect the brain from long-term dopamine loss. However, it can also cause hallucinations and other mental side effects due to its action on the mesolimbic pathway. Pergolide also affects the tuberoinfundibular pathway, reducing
How Permax works in the bodyThe dopamine D2 receptor is a protein found in cells that helps control certain functions. When activated, it can reduce the amount of calcium that flows into cells, as well as the activity of certain proteins. This can reduce the release of hormones from the pituitary gland and help improve coordination in people with movement disorders. Activating this receptor also blocks certain chemical signals from cells, which may help reduce inflammation and other effects.

When to interrupt dosage

The prescribed amount of Permax is contingent upon the diagnosed condition. The dosage likewise varies as per the technique of delivery (e.g. Oral or Tablet) outlined in the table beneath.
Condition
Dosage
Administration
Parkinson's Disease
, 0.05 mg, 0.25 mg, 1.0 mg
, Oral, Tablet - Oral, Tablet

Warnings

Permax has two contraindications, so it should not be taken while dealing with the conditions recorded in the following table.Permax Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Pergolide may interact with Pulse Frequency
Severe Hypersensitivity Reactions
Do Not Combine
Pergolide may interact with Pulse Frequency
There are 20 known major drug interactions with Permax.
Common Permax Drug Interactions
Drug Name
Risk Level
Description
4-Bromo-2,5-dimethoxyphenethylamine
Major
Pergolide may increase the hypertensive and vasoconstricting activities of 4-Bromo-2,5-dimethoxyphenethylamine.
4-Methoxyamphetamine
Major
Pergolide may increase the hypertensive and vasoconstricting activities of 4-Methoxyamphetamine.
5-methoxy-N,N-dimethyltryptamine
Major
Pergolide may increase the vasoconstricting activities of 5-methoxy-N,N-dimethyltryptamine.
Abediterol
Major
Pergolide may increase the hypertensive and vasoconstricting activities of Abediterol.
Adrafinil
Major
Pergolide may increase the hypertensive and vasoconstricting activities of Adrafinil.
Permax Toxicity & Overdose RiskThe toxic dose of this drug in rats is 15mg/kg. Overdosing may cause nausea, vomiting, seizures, low blood pressure, and increased activity of the central nervous system.
image of a doctor in a lab doing drug, clinical research

Permax Novel Uses: Which Conditions Have a Clinical Trial Featuring Permax?

45 active trials are in progress to assess Permax's potential to alleviate symptoms of Parkinson's Disease.
Condition
Clinical Trials
Trial Phases
Parkinson's Disease
39 Actively Recruiting
Not Applicable, Phase 1, Phase 4, Phase 2, Phase 3, Early Phase 1

Permax Reviews: What are patients saying about Permax?

5Patient Review
10/2/2007
Permax for Parkinson Symptoms
I was very disappointed that this drug was pulled off the market. I had been taking it for 10 years with no signs of heart valve problems.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about permax

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What was pergolide used for in humans?

"Treatments for Parkinson's disease other than Pergolide are often preferred because Pergolide is associated with a small risk of fibrotic reactions."

Answered by AI

What is Permax used for?

"Permax is a drug used to treat the symptoms of Parkinson's disease, such as stiffness, tremors, spasms, and poor muscle control. It is often used in combination with other medications."

Answered by AI

What is pergolide used for?

"Pergolide is a dopamine receptor agonist that is used to treat Parkinson's disease in some countries. It is typically taken in pill form."

Answered by AI

Why was pergolide taken off the market?

"The FDA today announced that manufacturers of the drug pergolide will be voluntarily removing it from the market due to the risk of serious damage to patients' heart valves."

Answered by AI

Clinical Trials for Permax

Have you considered Permax clinical trials? We made a collection of clinical trials featuring Permax, we think they might fit your search criteria.Go to Trials
Image of University of Kentucky in Lexington, United States.

Peripheral Nerve Tissue Implantation for Parkinson's Disease

45 - 75
All Sexes
Lexington, KY
The investigators propose a Phase I single surgical-center, double-blinded randomized parallel clinical trial involving bilateral autologous peripheral nerve tissue (PNT) delivery into the NBM or the alternate target also affecting cognition in this population, the substantia nigra (SN), to address "repair cell" support of these areas. Twenty-four participants with idiopathic Parkinson's Disease (PD) who have selected, qualified and agreed to receive as standard of care deep brain stimulation (DBS) will be enrolled and randomly allocated to receive bilateral PNT deployment to either the NBM or SN at the time of DBS surgery. Participants will be allocated equally among both assignments over the course of three years (8 Year 1, 10 Year 2, 6 Year 3). Participants will be evaluated for neurocognitive, motoric function, activities of daily living, and quality of life at enrollment before surgery, two-weeks after surgery, and 6, 12, and 24 months after surgery.
Phase 1
Recruiting
University of KentuckyCraig G van Horne, MD, PhD
Image of Austin Clinic PPD in Austin, United States.

LY3962681 for Parkinson's Disease

30 - 80
All Sexes
Austin, TX
The purpose of this study is to evaluate the safety, tolerability, and PK/PD of LY3962681 in healthy volunteers and patients with Parkinson's disease. The study will be comprised of two parts, the Single Ascending Dose (SAD) study and the Multiple Ascending Doses (MAD) study. During the SAD portion of the study, healthy volunteers will receive a single dose of LY3962681 or placebo (artificial cerebrospinal fluid (aCSF), no active drug) given into the spinal fluid. During the MAD portion of the study, patients with Parkinson's disease will receive two doses of either LY3962681 or placebo (aCSF) administered into the spinal fluid. * The treatment period in the SAD study will be 1 day. The treatment period in the MAD study will be 2 days, 12 to 24 weeks apart. * The follow-up period in the SAD study will be up to 52 weeks. The follow-up period in the MAD study will be up to 52 weeks post Dose 2.
Phase 1
Recruiting
Austin Clinic PPDTravis LewisPrevail Therapeutics
Image of Edward Hines Jr. VA Hospital, Hines, IL in Hines, United States.

Non-Invasive Vagal Nerve Stimulation for Parkinson's Disease

50 - 88
All Sexes
Hines, IL
More than 110,000 US Veterans living with Parkinson's disease (PD) currently receive PD-related care and services from the VA. Fall prevention is a priority for Veterans living PD. Gait disturbances are a major cause for functional dependence and the largest risk factor for falls, institutionalization, and death in PD. This SPiRE addresses the need to advance nonpharmacological rehabilitative health care of Veterans and maximizing functional outcomes by developing a non-invasive, neuromodulatory transcutaneous cervical Vagal Nerve Stimulation as an at-home intervention to improve gait and balance. This pilot clinical trial will assist with future efforts and priorities of the VA to prolong independent living and quality of life by minimizing gait and balance dysfunction experienced by Veterans living with PD.
Waitlist Available
Has No Placebo
Edward Hines Jr. VA Hospital, Hines, ILSandra L. Kletzel, PhD BA
Have you considered Permax clinical trials? We made a collection of clinical trials featuring Permax, we think they might fit your search criteria.Go to Trials
Image of San Francisco VA Medical Center, San Francisco, CA in San Francisco, United States.

Ketamine for Depression in Parkinson's Disease

40 - 80
All Sexes
San Francisco, CA
Parkinson's disease (PD) is a devastating illness that has a growing impact on Veterans. One of the most disabling symptoms is depression, which is common in PD and linked to poor quality of life and higher risk of suicide. Unfortunately, there is a lack of effective treatments for depression in PD. Ketamine, which has rapid and potent antidepressant effects, is a potential option but has not been tested in Veterans with PD. Studies in rodents show that ketamine may not only improve depression in PD, it may target two of the underlying drivers of the disease: (1) reduced neuroplasticity, or the brain's ability to adapt and remodel itself; and (2) elevated inflammation. The investigators are conducting a randomized, placebo-controlled study to examine if a dose of intravenous (IV) ketamine improves depression in Veterans with PD. The investigators will also examine ketamine's effects on neuroplasticity and inflammation, which will help us understand how ketamine works in PD and if it can be a useful treatment for Veterans with the disease. This study will lay groundwork for a larger clinical trial across multiple VA sites.
Phase 2
Recruiting
San Francisco VA Medical Center, San Francisco, CAEllen R Bradley, MD
Image of Hunter Holmes McGuire VA Medical Center, Richmond, VA in Richmond, United States.

Exoskeleton for Parkinson's Disease

18 - 90
All Sexes
Richmond, VA
Physical therapy approaches for balance and walking deficits in Parkinson's disease (PD) have limited effectiveness, with mostly short-lasting benefits. An exoskeleton is a device that straps to the legs and provides a passive force to assist people to better ambulate. The goal of this study is to establish the feasibility and safety of a lightweight exoskeleton on mobility and fall reduction in people with PD. As most PD patients eventually require assistive mobility devices, the exoskeleton represents a new option for increased, mobility, quality of life, and independence. Qualified subjects will come to the clinic twice weekly for eight weeks (16 total visits) and wear the exoskeleton device while walking under the supervision of a trained kinesiotherapist. Study staff will also interview participants and assess their PD symptoms, quality of life, and overall mobility. This study hopes to establish exoskeletons as modern, standard of care devices, which allow people with PD to maintain more independent and productive lives.
Recruiting
Has No Placebo
Hunter Holmes McGuire VA Medical Center, Richmond, VA (+1 Sites)Jessica B Lehosit
Image of Stanford Neuroscience Health Center in Stanford, United States.

STN+NBM DBS for Mild Cognitive Impairment in Parkinson's Disease

21 - 80
All Sexes
Stanford, CA
The goal of this clinical trial is to evaluate the safety and tolerability of a novel deep brain stimulation (DBS) of the Subthalamic Nucleus (STN) and Nucleus Basalis of Meynert (NBM) to treat cognitive and cognitive-motor symptoms in individuals with Parkinson's disease. The main question it aims to answer is: Is a combined deep brain stimulation approach targeting the STN and NBM with four DBS leads safe and tolerable for cognitive and cognitive-motor symptoms in individuals with Parkinson's disease with Mild Cognitive Impairment. Ten participants are anticipated to be enrolled. Participants will undergo a modification of the traditional STN DBS approach for motor symptoms of PD. In addition to the two leads placed within the STN, two additional leads will be placed with the NBM for treatment of cognitive and cognitive-motor symptoms. Novel stimulation patterns will be used within the NBM to target cognitive and cognitive-motor symptoms using an investigational software. Participants will be followed over two years while receiving this therapy with assessments at baseline and every six months. Assessments will include a combination of neuropsychological evaluations, cognitive assessments, motor tasks (including gait/walking), and questionnaires to evaluate the treatment. Two different surgical trajectories will be used, with half the cohort randomized to each group. This will allow comparison of the impact of surgical trajectory on the intervention.
Recruiting
Has No Placebo
Stanford Neuroscience Health CenterHelen M Bronte-Stewart, MD MSE
Have you considered Permax clinical trials? We made a collection of clinical trials featuring Permax, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security